An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Public ClinicalTrials.gov record NCT05732402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. Participants with IgAN and pMN may also receive povetacicept for an additional 52 weeks, if eligible.
Study identification
- NCT ID
- NCT05732402
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2023
- Primary completion
- Mar 1, 2028
- Completion
- Mar 1, 2028
- Last update posted
- Oct 13, 2025
2023 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site (523) | Phoenix | Arizona | 85016 | — |
| Investigational Site (501) | Phoenix | Arizona | 85302 | — |
| Investigational Site (524) | Tucson | Arizona | 85712 | — |
| Investigational Site (506) | Valencia | California | 91335 | — |
| Investigational Site (513) | Arvada | Colorado | 80002 | — |
| Investigational Site (512) | Orlando | Florida | 32806 | — |
| Investigational Site (525) | Tamarac | Florida | 33321 | — |
| Investigational Site (502) | Lawrenceville | Georgia | 30046 | — |
| The Johns Hopkins University School of Medicine | Baltimore | Maryland | 21224 | — |
| Investigational Site (503) | Boston | Massachusetts | 02115 | — |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | — |
| Investigational Site (509) | Newark | New Jersey | 07103 | — |
| Investigational Site (511) | Albany | New York | 12209 | — |
| Investigational Site (508) | Brooklyn | New York | 11203 | — |
| Investigational Site (518) | Bethlehem | Pennsylvania | 18017 | — |
| Investigational Site (118) | Colleyville | Texas | 76034 | — |
| Investigational Site (516) | Houston | Texas | 77054 | — |
| Investigational Site (526) | Irving | Texas | 75061 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05732402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2025 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05732402 live on ClinicalTrials.gov.